Integrating Optimal Use of Echocardiography and Biomarkers in Heart Disease

被引：0
作者：
Gagandeep S. Gurm
Christopher R. deFilippi
机构：
[1] The Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201
来源：
Current Cardiovascular Imaging Reports | 2012年 / 5卷 / 6期
关键词：
Echocardiography; Heart failure; Natriuretic peptides;
D O I：
10.1007/s12410-012-9167-z
中图分类号：
学科分类号：
摘要：
Echocardiography remains the primary modality to identify cardiac structural and functional abnormalities in patients with signs and symptoms of heart failure. Echocardiography may also have a role in identifying patients at risk of heart failure, in other words, differentiating patients from ACC/AHA stage A (risk factors for heart failure) to stage B (structural abnormalities in the absence of symptoms). In recent years soluble (blood based) cardiac specific biomarkers have been broadly introduced into clinical practice for the diagnosis of acute myocardial infarction (cardiac troponins) and diagnosing and prognosticating patients with heart failure (the natriuretic peptide tests, B-type natriuretic peptide [BNP] and the amino-terminal of proBNP [NT-proBNP]). Specifically, a large number of studies have evaluated the use of natriuretic peptides to complement the results of echocardiography in a spectrum of cardiovascular diseases ranging from asymptomatic community based populations to prognosticating patients with cardiomyopathies, valve disease and pulmonary embolism. The focus of this review will be to assess the state of the evidence from a variety of scenarios where natriuretic peptide testing and echocardiography can provide complementary information for diagnosis, prognosis and potentially guiding therapy. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：444 / 451
页数：7
相关论文
共 81 条
  • [1] Roger V.L., Go A.S., Lloyd-Jones D.M., Et al., Executive summary: heart disease and stroke statistics-2012 update: a report from the American heart association, Circulation, 125, 1, pp. 188-197, (2012)
  • [2] Wang T.J., Larson M.G., Levy D., Et al., Plasma natriuretic peptide levels and the risk of cardiovascular events and death, N Engl J Med, 350, 7, pp. 655-663, (2004)
  • [3] Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett Jr. J.C., Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study, Circulation, 109, 25, pp. 3176-3181, (2004)
  • [4] Saunders J.T., Nambi V., de Lemos J.A., Et al., Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study, Circulation, 123, 13, pp. 1367-1376, (2011)
  • [5] deFilippi C.R., de Lemos J.A., Christenson R.H., Et al., Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults, Jama, 304, 22, pp. 2494-2502, (2010)
  • [6] Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, 347, 20, pp. 1557-1565, (2002)
  • [7] Braunwald E., Biomarkers in heart failure, N Engl J Med, 358, 20, pp. 2148-2159, (2008)
  • [8] Kim H.N., Januzzi Jr. J.L., Biomarkers in the management of heart failure, Curr Treat Options Cardiovasc Med, 12, 6, pp. 519-531, (2010)
  • [9] Yamamoto K., Burnett Jr. J.C., Jougasaki M., Et al., Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy, Hypertension, 28, 6, pp. 988-994, (1996)
  • [10] Iwanaga Y., Nishi I., Furuichi S., Et al., B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure, J Am Coll Cardiol, 47, 4, pp. 742-748, (2006)
123456789